Highest-materiality recent filing
Tenaya shareholders approve amended equity plan adding 6.5M shares, elect directors
Shareholders approved amended 2021 Equity Incentive Plan with one-time increase of 6,509,966 shares (~3% of outstanding).
Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026
Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.
Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027
Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.
Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.
Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026
Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.
Director David Goeddel resigns from Tenaya board effective Jan 26, 2026
David Goeddel submitted resignation from the Board and all committees on Dec 31, 2025. Effective Jan 26, 2026.
Tenaya Therapeutics prices $60M public offering of 50M units at $1.20/unit; warrants at $1.50
Gross proceeds ~$60M from 50M units, each unit = 1 share + 1 warrant (5-yr, $1.50 exercise).
FDA lifts clinical hold on TN-201; TN-401 shows positive interim data in ARVC patients
FDA removed clinical hold on MyPEAK-1 trial for TN-201 gene therapy; protocol amendments implemented, dosing to resume.
Tenaya reports Q3 net loss $20.3M; FDA places clinical hold on TN-201 MyPEAK-1 trial
Net loss $20.3M ($0.12/share) vs $25.6M ($0.30) in Q3 2024; cash $56.3M, sufficient into H2 2026.
FDA places clinical hold on Tenaya's Phase 1b/2a TN-201 trial due to protocol amendment request
FDA requests protocol amendment to standardize patient monitoring and immunosuppression management across trial sites.
Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025
Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.
Tenaya Therapeutics shareholders elect all three Class I directors and ratify Deloitte as auditor
David Goeddel, Ph.D. elected with 80,444,762 votes for, 8,262,596 withheld.
Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026
Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.
Tenaya receives Nasdaq bid price deficiency notice; must regain compliance by Oct 13, 2025
Closing bid price of TNYA common stock below $1.00 for 30 consecutive business days through April 12, 2025.
Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026
Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).
Tenaya Therapeutics prices $52.5M public offering of units with warrants
Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.
Tenaya appoints interim PAO and reprices CEO underwater options to $1.21
Tomohiro Higa appointed Interim Principal Accounting Officer effective Feb 6, 2025; he remains SVP Finance.
Tenaya Therapeutics reprices underwater employee stock options to $1.21 per share
Repriced ~4.1M shares of underwater options with original exercise prices $3.06-$21.01 to $1.21 per share.
Tenaya Therapeutics' SVP & Interim PAO Chihiro Saito resigns effective Dec 16, 2024
Chihiro Saito resigned as SVP, Accounting and Financial Operations and Interim Principal Accounting Officer.
Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients
TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.
Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.
Tenaya Therapeutics adopts 2024 Inducement Plan, reclassifies director to balance board
Karah Parschauer reclassified from Class I to Class II director to balance board classes (3 per class).
Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs
Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.
Tenaya Therapeutics CFO Leone Patterson resigning effective Aug 14, 2024
Leone Patterson, Chief Financial and Business Officer, resigns to pursue another opportunity; will remain until August 14, 2024.
Tenaya Therapeutics Director Jin-Long Chen Resigns
Jin-Long Chen resigned as a director of Tenaya Therapeutics on June 25, 2024.
Tenaya stockholders elect three Class III directors, ratify Deloitte as auditor
Faraz Ali elected with 60,262,398 votes for, 157,949 withheld; broker non-votes 10,386,279.
Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025
Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.
Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.
Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company
Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.
Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya
On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity.
On June 25, 2024, Jin-Long Chen submitted his resignation as a director of Tenaya Therapeutics, Inc.
Max materiality 0.85 · Median 0.65 · Most common event other_material